Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00974
|
|||||
Drug Name |
Cefpodoxime
|
|||||
Synonyms |
(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CPDX; Cefpodoxim acid; Cefpodoxima; Cefpodoxima [Spanish]; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Cefpodoximum; Cefpodoximum [Latin]; Epoxim; Epoxim (TN); RU 51807; Vantin (TN)
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Bacterial infections [ICD11: 1A00-1H0Z] | Approved | [1] | |||
Therapeutic Class |
Antibiotics
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C15H17N5O6S2
|
|||||
Canonical SMILES |
COCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
|
|||||
InChI |
InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
|
|||||
InChIKey |
WYUSVOMTXWRGEK-HBWVYFAYSA-N
|
|||||
CAS Number |
CAS 82619-04-3
|
|||||
Pharmaceutical Properties | Molecular Weight | 427.5 | Topological Polar Surface Area | 210 | ||
Heavy Atom Count | 28 | Rotatable Bond Count | 7 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 11 | |||
XLogP |
-1.4
|
|||||
PubChem CID | ||||||
ChEBI ID |
CHEBI:3504
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
References | ||||||
1 | Cefpodoxime was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.